Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

XEN45 Gel Stent implant: results in primary open-angle glaucoma vs secondary open-angle glaucoma

Poster Details

First Author: N.Moura-Coelho PORTUGAL

Co Author(s):    S. Crisostomo   L. Costa   A. Basi�Â�­lio   M. Dutra-Medeiros   M. Sa Cardoso   T. Gomes     

Abstract Details


To evaluate and compare the efficacy and safety of the XEN45 Gel Stent Glaucoma Treatment System (Allergan, Irvine, CA) between patients with primary open-angle glaucoma (POAG) and patients with secondary open-angle glaucoma (SOAG).


The study was conducted at a tertiary center for Ophthalmology in Portugal, and reports the initial experience with XEN implantation at the national level.


Retrospective analysis of 19 eyes of 18 patients with medically refractory open-angle glaucoma who underwent XEN implantation at our institution. Clinical outcomes measured at 6-month follow-up included intra-ocular pressure (IOP) reduction, IOP reduction rate, reduction in number IOP-lowering drug requirements, required additional procedures, and complications.


11 eyes with POAG and 8 eyes with SOAG underwent XEN implant surgery. A significant reduction in IOP at 6-month post-surgery was observed in both POAG and SOAG patient groups (p-value = 0.021, p-value = 0.018, respectively). The median difference in IOP reduction between both groups was not statistically significant (p-value = 0.620), as were not median IOP reduction rate and the median reduction in IOP-lowering drug requirements post-operatively (p-value = 0.869 and p-value = 0.933, respectively). No major intra-operative or post-operative complications were observed; 3 patients in each group required additional procedures within the follow-up period.


In this study, the XEN stent showed good efficacy and safety profiles in lowering the IOP, with similar outcomes in both primary and secondary open-angle glaucoma. Larger, prospective studies are needed to further understand whether etiology of OAG may play a role in XEN surgery outcomes.

Financial Disclosure:


Back to Poster listing